Compare Stocks

Date Range: 

 Universe Pharmaceuticalse-therapeuticsAcasti PharmaNovoheartReNeuron Group
SymbolNYSE:UPCLON:ETXCVE:ACSTCVE:NVHLON:RENE
Price Information
Current Price$3.19GBX 29.25C$0.56C$0.53GBX 147.50
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.00.40.80.50.6
Analysis Score0.00.00.00.00.0
Community Score0.02.12.72.63.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.01.30.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$69.38 million£123.08 millionC$88.79 millionC$79.23 million£83.86 million
BetaN/AN/AN/AN/AN/A
Average Volume4,312,754928,843604,26133,593245,412
Sales & Book Value
Annual RevenueN/A£305,000.00C$81,000.00C$423,500.00£112,000.00
Price / SalesN/A403.531,383.55236.08748.77
CashflowN/AGBX 3.99 per shareC$0.15 per shareC$0.07 per shareGBX 31.02 per share
Price / CashN/A7.333.787.464.75
Book ValueN/AGBX 3.70 per shareC$0.17 per shareC$0.12 per shareGBX 20.80 per share
Price / BookN/A0.083.394.340.07
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AGBX (1)C$0.03C($0.04)GBX (45.90)
Trailing P/E Ratio0.00N/A16.47N/AN/A
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.30%0.41%27.62%11.98%
Current RatioN/A36.70%13.43%6.13%1.77%
Quick RatioN/A35.91%12.69%6.05%1.77%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
EmployeesN/A1632N/A62
Shares Outstanding21.75 million420.77 million200.12 million188.64 million56.86 million
Next Earnings DateN/AN/AN/AN/A7/19/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
ReNeuron Group (LON:RENE) Shares Cross Above 50-Day Moving Average of $126.56ReNeuron Group (LON:RENE) Shares Cross Above 50-Day Moving Average of $126.56
americanbankingnews.com - May 5 at 2:56 AM
ReNeuron Group (LON:RENE) Stock Price Passes Above Fifty Day Moving Average of $114.06ReNeuron Group (LON:RENE) Stock Price Passes Above Fifty Day Moving Average of $114.06
americanbankingnews.com - April 17 at 1:30 AM
ReNeuron signs new collaboration agreementsReNeuron signs new collaboration agreements
sharecast.com - March 19 at 1:02 PM
AIM WINNERS & LOSERS: Futura Medical up on EU medical device clearanceAIM WINNERS & LOSERS: Futura Medical up on EU medical device clearance
lse.co.uk - March 19 at 8:00 AM
ReNeuron inks commercial collaboration deals for exosome platformReNeuron inks commercial collaboration deals for exosome platform
lse.co.uk - March 19 at 8:00 AM
ReNeuron unveils new collaborations, data findings on exosome technology platformReNeuron unveils new collaborations, data findings on exosome technology platform
proactiveinvestors.co.uk - March 19 at 8:00 AM
ReNeuron jumps after unveiling new collaborations on exosome technology platformReNeuron jumps after unveiling new collaborations on exosome technology platform
proactiveinvestors.co.uk - March 19 at 8:00 AM
ReNeuron begins search for new chief financial officerReNeuron begins search for new chief financial officer
proactiveinvestors.co.uk - March 12 at 8:52 PM
ReNeuron Group plc - Appointment of Joint BrokerReNeuron Group plc - Appointment of Joint Broker
proactiveinvestors.co.uk - February 25 at 3:59 AM
Exosome Diagnostic and Therapeutics Market 2021 to 2025 Growth Factors, Market Characteristics, Opportunities By Type Analysis and ForecastExosome Diagnostic and Therapeutics Market 2021 to 2025 Growth Factors, Market Characteristics, Opportunities By Type Analysis and Forecast
marketwatch.com - February 16 at 7:00 AM
ReNeuron Group plc - Total Voting RightsReNeuron Group plc - Total Voting Rights
proactiveinvestors.co.uk - February 1 at 12:24 PM
Clinical update - Treatment of first patient cohort completed in Phase 2a extension of retinal disease studyClinical update - Treatment of first patient cohort completed in Phase 2a extension of retinal disease study
pharmiweb.com - January 15 at 4:34 PM
Notification of Allowance granted for US patentNotification of Allowance granted for US patent
pharmiweb.com - December 17 at 3:06 PM
Director Deals - Reneuron Group PLC (RENE)Director Deals - Reneuron Group PLC (RENE)
stockmarketwire.com - December 16 at 11:02 PM
Reneuron Share News (RENE)Reneuron Share News (RENE)
lse.co.uk - December 11 at 2:32 PM
UK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support StudyUK TRADING UPDATE SUMMARY: ReNeuron Plans Fundraise To Support Study
lse.co.uk - November 25 at 10:19 PM
ReNeuron Group plc - Interim ResultsReNeuron Group plc - Interim Results
proactiveinvestors.com - November 25 at 10:19 PM
ReNeuron Group plc - Second Price Monitoring ExtnReNeuron Group plc - Second Price Monitoring Extn
proactiveinvestors.co.uk - November 24 at 6:04 PM
ReNeuron raising up to £15mln to fund two key R&D programmesReNeuron raising up to £15mln to fund two key R&D programmes
proactiveinvestors.co.uk - November 24 at 8:03 AM
Stem Cells Market Size to Rake USD 17.79 Billion by 2027Stem Cells Market Size to Rake USD 17.79 Billion by 2027
arnnet.com.au - October 29 at 7:56 AM
ReNeuron Group PLC Registered S (RQE1.SG)ReNeuron Group PLC Registered S (RQE1.SG)
au.finance.yahoo.com - October 10 at 4:34 AM
Global Exosome Therapeutic MarketGlobal Exosome Therapeutic Market
openpr.com - September 4 at 5:55 PM
Stem Cell Therapy Market: Overview, Opportunities, In-Depth Analysis and Forecasts, Outlook -2025Stem Cell Therapy Market: Overview, Opportunities, In-Depth Analysis and Forecasts, Outlook -2025
marketwatch.com - September 4 at 5:55 PM
Stem Cell Therapy Market Application, Revenue, Types, Trends in Future, Scope to 2025Stem Cell Therapy Market Application, Revenue, Types, Trends in Future, Scope to 2025
marketwatch.com - August 27 at 6:32 PM
ReNeuron confirms plan to reduce number of non-executive directors and appoint one from Obotritia CapitalReNeuron confirms plan to reduce number of non-executive directors and appoint one from Obotritia Capital
proactiveinvestors.co.uk - August 12 at 8:58 AM
DateCompanyBrokerageAction
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.